[go: up one dir, main page]

ES2428665B1 - Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization - Google Patents

Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization Download PDF

Info

Publication number
ES2428665B1
ES2428665B1 ES201230664A ES201230664A ES2428665B1 ES 2428665 B1 ES2428665 B1 ES 2428665B1 ES 201230664 A ES201230664 A ES 201230664A ES 201230664 A ES201230664 A ES 201230664A ES 2428665 B1 ES2428665 B1 ES 2428665B1
Authority
ES
Spain
Prior art keywords
composition
inflammation
prevention
treatment
oxidative stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201230664A
Other languages
Spanish (es)
Other versions
ES2428665A1 (en
Inventor
María Jesús GONZÁLEZ GARCÍA
Margarita Calonge Cano
Amalia ENRÍQUEZ DE SALAMANCA ALADRO
Michael E. Stern
Antonio ABENGÓZAR VELA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Valladolid
Allergan Inc
Original Assignee
Universidad de Valladolid
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Valladolid, Allergan Inc filed Critical Universidad de Valladolid
Priority to ES201230664A priority Critical patent/ES2428665B1/en
Priority to PCT/ES2013/070279 priority patent/WO2013164512A2/en
Publication of ES2428665A1 publication Critical patent/ES2428665A1/en
Application granted granted Critical
Publication of ES2428665B1 publication Critical patent/ES2428665B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005—Other compounding ingredients characterised by their effect
    • C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/261—Alcohols; Phenols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/267—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular.#La presente invención se refiere al uso de la quercetina (QCT) o de una composición que comprende QCT y al menos otro compuesto polifenólico, preferiblemente resveratrol (RES), para el tratamiento y/o prevención de lesiones o enfermedades que cursan con inflamación, estrés oxidativo y/o neovascularización ocular, preferiblemente del segmento anterior, más preferiblemente de la superficie ocular y aun más preferiblemente del epitelio corneal. La invención también se refiere al uso de la QCT y de dicha composición como agente antimicrobiano, antioxidante y antiinflamatorio en soluciones de limpieza y mantenimiento de lentes de contacto.Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization. # The present invention relates to the use of quercetin (QCT) or a composition comprising QCT and at least one other polyphenolic compound , preferably resveratrol (RES), for the treatment and / or prevention of lesions or diseases that occur with inflammation, oxidative stress and / or ocular neovascularization, preferably of the anterior segment, more preferably of the ocular surface and even more preferably of the corneal epithelium. The invention also relates to the use of QCT and said composition as an antimicrobial, antioxidant and anti-inflammatory agent in contact lens cleaning and maintenance solutions.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

Claims (1)



 imagen1image 1
ES201230664A 2012-05-04 2012-05-04 Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization Active ES2428665B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201230664A ES2428665B1 (en) 2012-05-04 2012-05-04 Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization
PCT/ES2013/070279 WO2013164512A2 (en) 2012-05-04 2013-05-06 Composition for use in the treatment and/or prevention of inflammation, oxidative stress and ocular neovascularization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230664A ES2428665B1 (en) 2012-05-04 2012-05-04 Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization

Publications (2)

Publication Number Publication Date
ES2428665A1 ES2428665A1 (en) 2013-11-08
ES2428665B1 true ES2428665B1 (en) 2014-10-01

Family

ID=48700616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230664A Active ES2428665B1 (en) 2012-05-04 2012-05-04 Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization

Country Status (2)

Country Link
ES (1) ES2428665B1 (en)
WO (1) WO2013164512A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941841C (en) 2014-03-28 2021-08-17 Hortus Novus Srl Compositions based on saffron for the prevention and/or treatment of degenerative eye disorders.
US10092585B2 (en) 2014-09-19 2018-10-09 Hortus Novus Srl Compositions based on saffron for the prevention and/or treatment of corneal dystrophies
IT202200002108A1 (en) 2022-02-07 2023-08-07 Indena Spa QUERCETIN-BASED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057473A1 (en) * 2001-01-17 2002-07-25 Young-Mee Park Method for inhibiting vegf and epo gene expression by quercetin
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
US20060127505A1 (en) 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
DE60321227D1 (en) * 2003-01-09 2008-07-03 Michael D Farley CYTOTOXIC PHARMACEUTICAL COMPOSITION
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
US20050220907A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Implanted medical devices with anti-inflammatory coatings
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
DE602006013787D1 (en) * 2006-03-28 2010-06-02 Epitech Group Srl A pharmaceutical composition for the treatment of pathologies caused by the general immune response
WO2008016095A1 (en) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
WO2008061536A1 (en) * 2006-11-22 2008-05-29 Ocumedic Aps Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
AU2010314956A1 (en) * 2009-11-06 2012-04-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye

Also Published As

Publication number Publication date
WO2013164512A2 (en) 2013-11-07
WO2013164512A3 (en) 2014-03-20
ES2428665A1 (en) 2013-11-08

Similar Documents

Publication Publication Date Title
ES2524320T3 (en) Composition for the prevention or treatment of disease associated with thrombus or embolus
CL2012001583A1 (en) Ophthalmic preparation comprising: a) povidone iodine, b) a cooling agent and c) one or more of camphor, borneol, lubricant, emollient, steroidal anti-inflammatory and non-steroidal anti-inflammatory; and its use for the treatment and / or prophylaxis of an eye disorder or infection.
CO2017004715A2 (en) Methods and formulations to treat vascular eye diseases
CL2017002527A1 (en) Use of formyl 2 peptide receptor agonists to treat inflammatory eye diseases. (divisional of application n ° 2485-2015).
UY32989A (en) CONCENTRATED THERAPEUTIC PHOSPHOLIPID COPOSITIONS
CL2017003138A1 (en) Tricyclic derivative compound, method of preparation thereof and pharmaceutical composition comprising it.
MX2018001472A (en) Use of cannabinoids in the treatment of epilepsy.
BR112014008789A2 (en) prevention and treatment of eye conditions
MX2021008702A (en) USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY.
CL2013002134A1 (en) Topical administration ophthalmic pharmaceutical composition comprising an androgen; and method to treat an eye condition resulting from an androgen deficiency.
MX2016014634A (en) COMPOUNDS FOR THE TREATMENT OF DISEASES AND OPHTHALMIC DISORDERS.
CL2010001406A1 (en) Ophthalmic pharmaceutical composition comprising povidone iodine, and a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial, an anti-allergic or an anti-glaucoma compound; and method to preserve the composition.
CL2018000413A1 (en) Composition and products comprising senescent cells for use in tissue regeneration
MX2016007658A (en) COMPOSITIONS BASED ON METHYL CYCLODEXTRINES FOR THE TREATMENT AND / OR PREVENTION OF DISEASES INCREASING THE LEVEL OF CHOLESTEROL HDL.
BR112018003892A2 (en) Pharmaceutical composition and method for reducing fat
UY32758A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPTICAL, NASAL OR OPHTHAL INFECTIONS
BR112014010376A2 (en) medicament for treating anterior eye disease comprising rebamipide and a tear retention agent
ES2428665B1 (en) Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization
CO7240418A2 (en) Dressing with a prolonged release of active agents
MX2016008429A (en) DERIVED FROM PIRANOCROMENIL PHENOL, AND PHARMACEUTICAL COMPOSITION TO TREAT A METABOLIC SYNDROME OR INFLAMMATORY DISEASE.
CO2017003840A2 (en) Heat sterilized formulation comprising chitosan and process for its preparation
BR112012028437A2 (en) ophthalmic solution and method for treating glaucoma or ocular hypertension
CO7131368A2 (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
BR112015005942A2 (en) cynara scolymus extracts, coffea spp. and olea europaea for treatment of metabolic syndrome
MX2019014667A (en) Treatment of cutaneous disorders.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2428665

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141001